2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T7b24,

Summary Table

Category	Detail
Risk Factors	Female sex, age > 50, early menarche (< 12), late menopause (> 55), nulliparity or first pregnancy after age 30, first-degree relative with breast cancer, BRCA1/BRCA2 mutation carriers, prior chest radiation (e.g., Hodgkin lymphoma treatment), obesity (postmenopausal), hormone replacement therapy (combined estrogen-progesterone), atypical ductal or lobular hyperplasia, personal history of breast cancer
Etiology	Multifactorial: cumulative estrogen exposure drives most sporadic cases; hereditary syndromes (BRCA1/2, Li-Fraumeni, Cowden syndrome) account for 5-10% of cases
Patient Presentation	Painless, hard, immobile breast mass with irregular borders; may present with nipple retraction, skin dimpling, bloody nipple discharge, or peau d'orange skin changes; some detected only on screening mammography
Classic Physical Exam	Fixed, non-tender mass in the upper outer quadrant; axillary lymphadenopathy; skin tethering or dimpling on arm elevation; nipple retraction or eczematous changes of the nipple (Paget disease); peau d'orange (lymphatic obstruction causing edema with pitting resembling orange peel); inflammatory breast cancer shows diffuse erythema, warmth, and edema without a discrete mass
Key Diagnostic Results	Mammography shows irregular spiculated mass or clustered microcalcifications; ultrasound distinguishes solid from cystic lesions; core needle biopsy is the confirmatory test providing histology, receptor status (ER, PR, HER2); staging with chest CT, bone scan, or PET-CT in advanced disease
Management	Surgical excision (lumpectomy + radiation or mastectomy), sentinel lymph node biopsy for staging, adjuvant chemotherapy based on stage and receptor status, endocrine therapy (tamoxifen for premenopausal, aromatase inhibitors for postmenopausal) for ER/PR-positive tumors, trastuzumab for HER2-positive tumors
Keywords	Spiculated mass, clustered microcalcifications, peau d'orange, bloody nipple discharge, BRCA mutation, sentinel lymph node biopsy, tamoxifen, aromatase inhibitor, trastuzumab, Paget disease of the nipple

1. Pathophysiology

Breast cancer arises from the epithelial cells lining the terminal duct-lobular unit. The two broad histologic categories are ductal (originating from ductal epithelium, approximately 70-80% of cases) and lobular (originating from lobular epithelium, approximately 10-15%). Each of these can be either in situ (confined within the basement membrane) or invasive (penetrating through the basement membrane into surrounding stroma), and this distinction is one of the most tested concepts in breast pathology.

Estrogen is the central hormonal driver in the majority of breast cancers. Estrogen binds to estrogen receptors on ductal epithelial cells and activates transcription of genes promoting cellular proliferation. This is why every major risk factor for breast cancer ties back to cumulative lifetime estrogen exposure: early menarche, late menopause, nulliparity, obesity in postmenopausal women (adipose tissue contains aromatase, which converts androgens to estrogen), and exogenous hormone replacement therapy. Understanding this hormonal axis explains why anti-estrogen therapies (tamoxifen, aromatase inhibitors) are cornerstones of treatment for receptor-positive disease.

In hereditary breast cancer, BRCA1 and BRCA2 are tumor suppressor genes involved in homologous recombination repair of double-stranded DNA breaks. Loss-of-function mutations in either gene impair DNA repair, leading to genomic instability and accelerated carcinogenesis. BRCA1 mutations are more frequently associated with triple-negative breast cancer (ER-negative, PR-negative, HER2-negative), which lacks targetable receptors and carries a worse prognosis. BRCA2 mutations tend to produce ER-positive tumors. Both confer elevated risk for ovarian cancer, which is why prophylactic bilateral salpingo-oophorectomy is discussed in confirmed carriers.

The physical findings in breast cancer are direct consequences of tumor biology. A spiculated, irregular mass results from desmoplastic reaction (fibrosis) around infiltrating tumor cells. Skin dimpling and nipple retraction occur when tumor invades and shortens the Cooper ligaments or the lactiferous ducts, respectively. Peau d'orange results from tumor cells obstructing dermal lymphatics, causing lymphedema with tethering at the points where skin is anchored to deeper structures by Cooper ligaments. In inflammatory breast cancer, tumor emboli extensively plug dermal lymphatics, producing diffuse edema, erythema, and warmth that mimics mastitis but without fever or leukocytosis and, critically, without a palpable discrete mass.

2. Classification and Clinical Manifestation

Histologic Classification

Type	Subtype	Key Features
Non-invasive (in situ)	Ductal carcinoma in situ (DCIS)	Malignant cells confined within the duct; detected by clustered microcalcifications on mammography; does not metastasize but is a precursor to invasive ductal carcinoma; comedonecrosis subtype is higher grade
	Lobular carcinoma in situ (LCIS)	Incidental finding; does not form a mass or calcifications; considered a risk marker for future invasive cancer in either breast (not a direct precursor); often managed with observation and risk reduction
Invasive	Invasive ductal carcinoma (IDC)	Most common type (70-80%); forms a hard, gritty, spiculated mass; variable receptor expression
	Invasive lobular carcinoma (ILC)	Second most common (10-15%); grows in single-file "Indian file" pattern; often multifocal and bilateral; may be difficult to detect on mammography due to diffuse infiltration without a discrete mass; more commonly ER/PR-positive
	Medullary carcinoma	Soft, well-circumscribed, fleshy mass with lymphocytic infiltrate; associated with BRCA1; better prognosis despite aggressive histology; often triple-negative
	Tubular carcinoma	Well-differentiated, excellent prognosis; small tubular structures; often found on screening
	Mucinous (colloid) carcinoma	Older patients; produces extracellular mucin pools; favorable prognosis
	Inflammatory breast cancer	Clinical diagnosis: diffuse erythema, edema, peau d'orange without discrete mass; dermal lymphatic invasion on biopsy; T4d staging regardless of tumor size; aggressive, treated with neoadjuvant chemotherapy first

Molecular Classification

Subtype	ER/PR	HER2	Typical Features	Treatment Implications
Luminal A	Positive	Negative	Low grade, slow growing, best prognosis	Endocrine therapy alone often sufficient
Luminal B	Positive	Positive or Negative	Higher grade than Luminal A, higher Ki-67	Endocrine therapy + chemotherapy, add trastuzumab if HER2-positive
HER2-enriched	Negative	Positive	Aggressive, but targetable	Trastuzumab-based regimens (+ pertuzumab in many protocols)
Triple-negative (Basal-like)	Negative	Negative	Aggressive, no targeted receptor therapy, associated with BRCA1	Chemotherapy is the primary systemic option; PARP inhibitors (olaparib) for BRCA-mutated tumors

Staging Overview (Simplified TNM)

Stage	Description	5-Year Survival (approximate)
0	In situ (DCIS or LCIS)	~99%
I	Tumor 2 cm or less, no lymph node involvement	~95%
II	Tumor > 2 cm or limited axillary lymph node involvement	~85%
III	Locally advanced: large tumor, extensive nodal involvement, chest wall or skin invasion	~55-70%
IV	Distant metastasis (bone, liver, lung, brain)	~25-30%

3. Diagnostic Workup

Test	Role	Key Findings
Mammography	Best initial test for screening and evaluation of a suspicious mass in women aged 40 and above	Spiculated mass, clustered microcalcifications (DCIS), architectural distortion; BI-RADS classification guides next steps
Ultrasound	First-line for women under 30 or pregnant women; adjunct to mammography to distinguish solid from cystic	Irregular hypoechoic solid mass with posterior acoustic shadowing favors malignancy; simple cyst (anechoic, smooth borders, posterior enhancement) is benign
Breast MRI	High sensitivity; used for screening BRCA carriers, evaluating extent of disease, or detecting occult primary in axillary nodal metastasis	Enhancing mass with irregular margins; also used to assess contralateral breast
Core needle biopsy	Confirmatory test (gold standard for tissue diagnosis)	Provides histologic type, grade, and receptor status (ER, PR, HER2, Ki-67); preferred over fine-needle aspiration because it preserves tissue architecture
Sentinel lymph node biopsy	Intraoperative staging of axillary nodes	Identifies the first draining node using technetium-99m and/or blue dye; if negative, no further axillary dissection is needed
Staging imaging	CT chest/abdomen, bone scan, or PET-CT for stage III-IV	Bone metastases (most common distant site), liver, lung, brain
Genetic testing	BRCA1/BRCA2 testing for high-risk patients	Family history of breast/ovarian cancer, bilateral breast cancer, male breast cancer, Ashkenazi Jewish ancestry

Mammography is the best initial test for any woman aged 40 or older presenting with a breast complaint. Standard screening recommendations begin at age 40-50 depending on the guideline source, performed every 1-2 years. The hallmark mammographic finding of invasive cancer is a spiculated mass with irregular borders. DCIS classically presents as clustered microcalcifications without a mass. The BI-RADS scoring system standardizes reporting: BI-RADS 0 requires additional imaging, BI-RADS 1-2 are negative or benign, BI-RADS 3 is probably benign (short-interval follow-up), BI-RADS 4-5 are suspicious or highly suggestive of malignancy (requiring biopsy), and BI-RADS 6 is known malignancy.

For women under 30, ultrasound is the initial imaging modality because younger breast tissue is dense and mammography has lower sensitivity in this group. Ultrasound is also used to determine whether a palpable mass is cystic (likely benign, can be observed or aspirated) or solid (requires biopsy if suspicious features are present).

Core needle biopsy is the confirmatory test. This is a critical exam concept: do not jump to excisional biopsy or mastectomy before tissue diagnosis. Core biopsy is preferred over fine-needle aspiration because it provides histologic architecture necessary for distinguishing invasive from in situ disease and allows receptor testing (ER, PR, HER2). A question presenting a palpable breast mass with suspicious imaging should lead to core needle biopsy as the next step, not immediate surgery.

Breast MRI has the highest sensitivity of any imaging modality for breast cancer but lower specificity (many false positives). It is reserved for screening BRCA mutation carriers, evaluating the extent of known cancer, assessing for multifocal or bilateral disease, and identifying an occult primary tumor when axillary node metastasis is found without a detectable breast lesion.

4. Management and Treatment

Clinical Scenario	Management
DCIS	Lumpectomy + radiation therapy; total mastectomy without radiation is an alternative; tamoxifen for ER-positive DCIS to reduce recurrence risk
LCIS	Observation with enhanced screening (mammography + MRI); chemoprevention with tamoxifen or raloxifene to reduce future risk; bilateral prophylactic mastectomy in select high-risk patients
Early-stage invasive (Stage I-II)	Lumpectomy + sentinel lymph node biopsy + adjuvant radiation; OR modified radical mastectomy; adjuvant systemic therapy based on receptor status and tumor characteristics
Locally advanced (Stage III)	Neoadjuvant chemotherapy to downstage tumor, followed by surgery and radiation; adjuvant systemic therapy based on receptor status
Inflammatory breast cancer	Neoadjuvant chemotherapy first (never primary surgery); modified radical mastectomy after response; adjuvant radiation; systemic therapy
Metastatic (Stage IV)	Systemic therapy (palliative intent): endocrine therapy for ER-positive, trastuzumab-based regimens for HER2-positive, chemotherapy for triple-negative; surgery and radiation for palliation only

Surgical Options

Breast-conserving surgery (lumpectomy) with adjuvant whole-breast radiation has equivalent overall survival to mastectomy for early-stage disease. This equivalence is one of the most commonly tested facts. Lumpectomy requires negative surgical margins; if margins are positive, re-excision or mastectomy is performed. Contraindications to lumpectomy include multicentric disease (tumor in more than one quadrant), prior radiation to the chest wall, inability to achieve negative margins, and pregnancy (radiation is contraindicated during pregnancy, though lumpectomy can be performed with radiation deferred to the postpartum period).

Sentinel lymph node biopsy (SLNB) has replaced routine axillary lymph node dissection for clinically node-negative patients. The sentinel node is identified by injecting technetium-99m sulfur colloid and/or isosulfan blue dye near the tumor or subareolarly. If the sentinel node is free of metastasis, no further axillary surgery is needed, significantly reducing the risk of lymphedema. If the sentinel node is positive, axillary lymph node dissection or axillary radiation is considered depending on the clinical scenario.

Adjuvant Systemic Therapy

Endocrine therapy is indicated for all ER-positive and/or PR-positive tumors:

For premenopausal women, tamoxifen 20 mg daily for 5-10 years is standard. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist at the breast and an agonist at the uterus and bone. Because of its agonist effect on the endometrium, it carries an increased risk of endometrial cancer and thromboembolic events (deep vein thrombosis, pulmonary embolism). Any postmenopausal bleeding in a patient on tamoxifen should prompt endometrial biopsy.

For postmenopausal women, aromatase inhibitors (anastrozole, letrozole, or exemestane) are preferred because they block peripheral conversion of androgens to estrogen by inhibiting aromatase. They are more effective than tamoxifen in postmenopausal patients but cause bone loss (osteoporosis) and arthralgias as notable side effects. Aromatase inhibitors are contraindicated in premenopausal women because the resulting drop in estrogen triggers a compensatory rise in gonadotropin secretion, which stimulates the ovaries, paradoxically increasing estrogen levels.

Trastuzumab (Herceptin) is a monoclonal antibody targeting HER2 (ErbB2) and is added to chemotherapy for all HER2-positive tumors. Treatment duration is typically 1 year of adjuvant trastuzumab. The major side effect is cardiotoxicity (decreased left ventricular ejection fraction), requiring baseline and periodic echocardiography during treatment. Trastuzumab should not be given concurrently with anthracyclines (e.g., doxorubicin) because of overlapping cardiac toxicity; these are given sequentially instead.

Chemotherapy regimens commonly include anthracycline-based (doxorubicin + cyclophosphamide) followed by taxane-based (paclitaxel or docetaxel) protocols. Doxorubicin has a cumulative dose-dependent risk of dilated cardiomyopathy (lifetime dose limit approximately $450\ mg/m^2$). Cyclophosphamide carries risk of hemorrhagic cystitis (prevented with mesna hydration).

PARP inhibitors (olaparib, talazoparib) are approved for BRCA-mutated, HER2-negative breast cancer. PARP inhibitors exploit the concept of synthetic lethality: cells with defective homologous recombination (from BRCA mutation) cannot repair DNA damage when PARP-mediated base excision repair is also blocked, leading to cell death.

Risk Reduction in BRCA Carriers

Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90%. Bilateral salpingo-oophorectomy reduces ovarian cancer risk and, in premenopausal women, also reduces breast cancer risk by removing the primary source of estrogen. Enhanced screening with annual mammography alternating with breast MRI every 6 months (beginning at age 25-30) is recommended for carriers who decline prophylactic surgery.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Fibroadenoma	Presents as a breast mass in a young woman; may overlap with early cancer presentation	Fibroadenoma is well-circumscribed, mobile ("breast mouse"), rubbery, and painless in a woman typically under 35; ultrasound shows a well-defined, homogeneous solid lesion without suspicious features
Fibrocystic changes	Breast lumps, pain, and fullness; common reason for breast evaluation	Bilateral, cyclical tenderness and lumpiness that worsens premenstrually and resolves after menses; mammography and ultrasound show cysts without solid suspicious components
Fat necrosis	Can present as a firm, irregular mass with skin retraction, mimicking carcinoma on exam and imaging	History of trauma or prior surgery to the breast; mammography may show oil cyst or dystrophic calcifications (coarse, eggshell-like, not the fine clustered microcalcifications of DCIS)
Phyllodes tumor	Large, rapidly growing breast mass; can be malignant	Rapidly enlarging, smooth, well-circumscribed mass; occurs in women aged 40-50; histology shows leaf-like stromal projections; treatment is wide local excision with negative margins (no lymph node dissection needed because it rarely metastasizes to nodes)
Mastitis / Breast abscess	Erythema, warmth, and swelling of the breast, mimicking inflammatory breast cancer	Mastitis occurs in lactating women, presents with fever and leukocytosis, responds to antibiotics (dicloxacillin or cephalexin); inflammatory breast cancer does NOT respond to antibiotics, has no fever, and shows dermal lymphatic invasion on biopsy
Paget disease of the nipple	Eczematous, crusting lesion of the nipple	Paget disease IS a form of breast cancer (underlying DCIS or invasive carcinoma in nearly all cases); the discriminator here is against eczema or contact dermatitis, which is bilateral, pruritic, and responds to topical steroids. Unilateral, persistent nipple changes that do not respond to topical treatment require biopsy to rule out Paget disease
Intraductal papilloma	Bloody nipple discharge, which also raises concern for cancer	Most common cause of bloody nipple discharge in a premenopausal woman; typically a solitary lesion near the areola; ductogram or ultrasound shows an intraductal mass; biopsy distinguishes from papillary carcinoma
Male breast cancer	Rare but testable; subareolar mass in a male patient	Associated with Klinefelter syndrome (47,XXY), BRCA2 mutations, liver cirrhosis (hyperestrogenism), and obesity; distinguish from gynecomastia, which is bilateral, concentric, tender, and benign

6. Traps and High-Yield Pearls

The most common trap on breast cancer questions is confusing the next step in workup. When a woman over 30 presents with a palpable breast mass, the next step is mammography (or ultrasound if under 30), followed by core needle biopsy if imaging is suspicious. Students frequently jump straight to excisional biopsy or surgery without obtaining tissue diagnosis first. Similarly, a common error is selecting fine-needle aspiration over core needle biopsy; core biopsy is preferred because FNA cannot distinguish invasive from in situ disease and cannot provide receptor status.

Another frequently tested concept is the distinction between DCIS and LCIS. DCIS is a true precursor lesion confined to the duct, detected by microcalcifications on mammography, and treated with excision. LCIS does not form a mass or calcifications, is usually an incidental finding on biopsy for another indication, and is considered a bilateral risk marker rather than a direct precursor. LCIS increases the risk of developing invasive cancer in either breast, not just the ipsilateral side, which is why management is observation with enhanced screening or chemoprevention rather than excision.

The equivalence of lumpectomy plus radiation and mastectomy for early-stage disease is tested repeatedly. Students sometimes assume mastectomy is superior, but randomized controlled trials have shown no difference in overall survival. The critical caveat is that lumpectomy requires adjuvant radiation and negative margins.

For pharmacology, the key trap involves aromatase inhibitors in premenopausal women. Aromatase inhibitors should never be used in premenopausal patients unless ovarian suppression is achieved first (with GnRH agonists or oophorectomy), because intact ovarian function will compensate for peripheral aromatase blockade by increasing gonadotropin-driven estrogen production.

Tamoxifen's dual action is heavily tested: it is an estrogen antagonist at the breast (therapeutic) but an estrogen agonist at the endometrium (increasing the risk of endometrial hyperplasia and carcinoma) and at bone (protective against osteoporosis, unlike aromatase inhibitors which worsen bone loss).

Finally, any question presenting a breast that is diffusely erythematous, edematous, and warm without a discrete mass and without response to antibiotics should immediately raise concern for inflammatory breast cancer. The biopsy will show dermal lymphatic invasion. This is a clinical and pathologic diagnosis, staged as T4d regardless of tumor size, and requires neoadjuvant chemotherapy before any surgical intervention. Performing upfront mastectomy on inflammatory breast cancer is a classic incorrect answer.

The core competency being tested across breast cancer questions is the ability to correctly sequence the diagnostic workup (imaging before biopsy, biopsy before surgery), match the treatment to receptor and menopausal status, and recognize presentations that deviate from the typical painless lump (inflammatory breast cancer, Paget disease, male breast cancer).

1e:["$","$L2d",null,{"article":{"id":"0574c8e2-3695-486d-8880-5c226cbdf90c","title":"Karsinoma Payudara","content":"$2e","category":"Reproduksi","created_at":"2026-05-16T17:50:53.679275+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]